Biotech | August 17, 2021
Indian pharma’s vaccine opportunity at US $ 10-11 billion
Domestic market and developing countries will need doses of Indian vaccines
Domestic market and developing countries will need doses of Indian vaccines
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
Nearly 6,000 patients have been treated with the drug since 2017
Deal signed with AOP Orphan for US commercial rights
FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Subscribe To Our Newsletter & Stay Updated
